News about Vytorin has a way of pushing everything else about Merck and Schering-Plough to the wayside. But the two companies did indeed report their earnings yesterday, after their Vytorin-related delay contributed to big drops in the companies’ shares. Here’s a recap.
For Merck, prior concern from Wall Street about sales of cervical-cancer vaccine Gardasil [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment